US64132K2015 - NBSE - A3EHBD (XNCM)
NEUBASE THERAPEUT. DL-,01 Acción
Sin cotización
Performance
Day | Week | Month | 3 Months | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|---|
- | - | - | - | -1,48 % | -42,73 % | -99,75 % |
Company Profile for NEUBASE THERAPEUT. DL-,01 Share
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Company Data for NEUBASE THERAPEUT. DL-,01 Share
Name NEUBASE THERAPEUT. DL-,01
Company NeuBase Therapeutics, Inc.
Symbol NBSE
Primary Exchange
Frankfurt
WKN A3EHBD
ISIN US64132K2015
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Mr. Todd P. Branning
Country United States of America
Currency EUR
Employees 0,0 T
Address 350 Technology Drive, 15219 Pittsburgh
IPO Date 2004-05-28
ID Changes
Date | From | To |
---|---|---|
16.07.2019 | OHRP | NBSE |
Ticker Symbols
Name | Symbol |
---|---|
NASDAQ | NBSE |
More Shares
Investors who NEUBASE THERAPEUT. DL-,01 hold also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.